HF
ACRV icon

HRT Financial’s Acrivon Therapeutics ACRV Stock Holding History

HRT Financial’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18K Buy
+10,316
New +$17.5K ﹤0.01% 3935
2025
Q3 		– Sell
-145,895
Closed -$173K – 2778
2025
Q2 		$173K Buy
+145,895
New +$200K ﹤0.01% 2105

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial's ACRV Position: Q2 2026 in Review

HRT Financial opened a new position in Acrivon Therapeutics (ACRV) in Q2 2026: 10,316 shares worth $18K. The stake represents ﹤0.01% of the portfolio and ranks #3935 among its holdings. This is a return to the name: HRT Financial previously reported a position in ACRV as recently as Q2 2025.

HRT Financial first reported a position in ACRV in Q2 2025 and has held it in 2 quarters since. The position peaked at $173K in Q2 2025. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • HRT Financial held 10,316 shares of Acrivon Therapeutics worth $18K as of Q2 2026.
  • Acrivon Therapeutics was a new HRT Financial position in Q2 2026.
  • Acrivon Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3935 holding.
  • HRT Financial first reported a position in Acrivon Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • HRT Financial's Acrivon Therapeutics position peaked at $173K in Q2 2025.
  • 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.